2221 - 2230 of 5832 Results
Title
Year
-
OPENTitle: Lifestyle Factors and Parkinson’s Disease Risk in a Rural New England Case-Control StudyJournal Name: Parkinson's DiseasePublisher: Hindawi LimitedVol: 2021Issue #:Start Page: 1End Page: 7Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1155/2021/5541760Best OA location URL: https://downloads.hindawi.com/journals/pd/2021/5541760.pdfCitation Count: 5
-
OPENTitle: SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s diseaseJournal Name: Molecular NeurodegenerationPublisher: Springer Science and Business Media LLCVol: 16Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13024-021-00468-xBest OA location URL: https://molecularneurodegeneration.biomedcentral.com/counter/pdf/10.1186/s13024-021-00468-xCitation Count: 12
- Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson’s disease2021OPENTitle: Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson’s diseaseJournal Name: Cell ReportsPublisher: Elsevier BVVol: 36Issue #: 1Start Page: 109333End Page: 109333Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.celrep.2021.109333Best OA location URL: http://www.cell.com/article/S2211124721007099/pdfCitation Count: 32
- Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies2021OPENTitle: Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III StudiesJournal Name: CNS DrugsPublisher: Springer Science and Business Media LLCVol: 35Issue #: 7Start Page: 781End Page: 794Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40263-021-00826-9Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40263-021-00826-9.pdfCitation Count: 14
-
OPENTitle: Genetic diversity of axon degenerative mechanisms in models of Parkinson's diseaseJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 155Issue #:Start Page: 105368End Page: 105368Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.nbd.2021.105368Best OA location URL: https://doi.org/10.1016/j.nbd.2021.105368Citation Count: 18
- Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia—The SPASTOX Trial2021OPENTitle: Letter to the Editor: Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia—The SPASTOX TrialJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 7Start Page: 1733End Page: 1733Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28659Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.28659Citation Count: 1
-
OPENTitle: Comparison between four published definitions of hyposmia in Parkinson's diseaseJournal Name: Brain and BehaviorPublisher: WileyVol: 11Issue #: 8Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/brb3.2258Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/brb3.2258Citation Count: 7
-
OPENTitle: Correction: Data Sharing Goals for Nonprofit Funders of Clinical TrialsJournal Name: Journal of Participatory MedicinePublisher: JMIR Publications Inc.Vol: 13Issue #: 2Start Page: e31371End Page: e31371Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.2196/31371Best OA location URL: https://jopm.jmir.org/2021/2/e31371/PDFCitation Count: 0
- Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial2021OPENTitle: Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept TrialJournal Name: Movement DisordersPublisher: WileyVol: 36Issue #: 10Start Page: 2408End Page: 2412Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28702Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596433Citation Count: 14
- A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease2021OPENTitle: A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 89Issue #:Start Page: 63End Page: 72Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.06.023Best OA location URL: http://www.prd-journal.com/article/S1353802021002431/pdfCitation Count: 22